Treatment of dyskinesia related disorders

Details for Australian Patent Application No. 2010217059 (hide)

Owner H. Lundbeck A/S

Inventors Wikstrom, Hakan; Jorgensen, Morten; Mork, Niels; Larsen, Jennifer; Torup, Lars; Bang-Andersen, Benny

Agent Spruson & Ferguson

Pub. Number AU-B-2010217059

PCT Pub. Number WO2010/097092

Priority 61/155,953 27.02.09 US; PA 200900280 27.02.09 DK; 61/155,943 27.02.09 US; 61/155,966 27.02.09 US; PA 200900281 27.02.09 DK; PA 200900273 27.02.09 DK

Parent 2008291425

Filing date 26 February 2010

Wipo publication date 2 September 2010

Acceptance publication date 30 August 2012

International Classifications

A61K 31/473 - ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines

A61K 31/4741

A61P 25/00 Drugs for disorders of the nervous system

A61P 25/14 Drugs for disorders of the nervous system

A61P 25/16 Drugs for disorders of the nervous system

C07D 491/04 Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or

Event Publications

11 August 2011 PCT application entered the National Phase

  PCT publication WO2010/097092 Priority application(s): WO2010/097092

30 August 2012 Application Accepted

  Published as AU-B-2010217059

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2010217061-Multi-point touch screen operating tool

2010217058-Methods of administering (4aR, 1OaR)-I-n-propyl-I, 2,3,4a7 S1IO7 IOaoctahydrobenzo (g) quinoline-6,7-diol and related compounds across the oral mucosa, the nasal mucosa or the skin and pharmaceutical compositions thereof